financetom
Business
financetom
/
Business
/
Shift to 5G: India looks to boost equipment production to remove bottlenecks
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Shift to 5G: India looks to boost equipment production to remove bottlenecks
Nov 28, 2022 4:29 AM

Along with the rollout of 5G services, the government is preparing to boost domestic telecom equipment production. According to people in the know, Telecom Minister Ashwini Vaishnav has also called a meeting with the domestic telecom equipment manufacturers on December 3 to discuss how bottlenecks related to domestic production can be addressed.

The CEOs of Dixion, ITI, Tejas, HFCL Shyam Telecom, Nokia, and Samsung will reportedly attend the meeting.

Discussion Points

The government is likely to discuss supply chain-related problems that the companies which have already gotten approvals under the PLI (Production Linked Incentive) and DLI (Design Linked Incentive) schemes are facing.

The discussion will also see talks about providing assistance to the companies with customs and production licences.

Also Read: 5G is here — but a lot needs to be done to feel its full force

Talking about the issue, Anand Agarwal, Group CEO at Sterlite Tech, told CNBC_TV18 that demand from the Europe and US markets is strong.

“We continue to see very strong capex investments on the back of 5G fibre to the home and it is very large spends, which are committed by the government. Just the US market itself, the government has committed $65 billion for broadband connectivity. Similarly, countries like the UK, Germany and of course India have projects like BharatNet. So all of this caters to very strong auto booking for us,” he added.

Also Read: Indian telecom gear firms get mandate from Railways for 5G trial between Palwal-Mathura

Watch the accompanying video for more.

(Edited by : Abhishek Jha)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved